https://www.scisync.org/2026/10/22/p079-12-relation-of-biomedical-laboratory-scientist-in-cancer-genomic-medicine/2026-10-22T13:26:40-04:00https://www.scisync.org/2026/10/22/p079-8-establishment-for-institutional-and-multidisciplinary-team-approach-for-home-visiting-injection-chemotherapy/2026-10-22T13:26:41-04:00https://www.scisync.org/2026/10/22/p079-4-establishment-of-database-for-immune-checkpoint-inhibitor-treated-patients-and-analysis-of-immune-related-adverse-events/2026-10-22T13:26:42-04:00https://www.scisync.org/2026/10/22/p078-6-comprehensive-genomic-profiling-in-non-targetable-advanced-nsclc-patients/2026-10-22T13:26:42-04:00https://www.scisync.org/2026/10/22/p078-1-lutein-and-3-epilutein-as-novel-therapeutic-agents-for-glioblastoma-preclinical-evaluation-of-anti-tumor-efficacy/2026-10-22T13:26:43-04:00https://www.scisync.org/2026/10/22/p077-6-clinical-utility-of-plasma-cfdna-liquid-cgp-in-cancer-a-retrospective-study-at-our-institution/2026-10-22T13:26:44-04:00https://www.scisync.org/2026/10/22/p077-3-modeling-the-pre-test-ctdna-detectability-in-liquid-cgp-for-advanced-pancreatic-cancer/2026-10-22T13:26:44-04:00https://www.scisync.org/2026/10/22/p076-4-albumin-associated-plasma-proteins-a-novel-diagnostic-avenue-for-lung-cancer/2026-10-22T13:26:45-04:00https://www.scisync.org/2026/10/22/p075-3-orbital-metastasis-in-her2-positive-breast-cancer-a-case-report/2026-10-22T13:26:45-04:00https://www.scisync.org/2026/10/22/p075-1-a-case-of-undifferentiated-pleomorphic-sarcoma-of-the-breast-initially-treated-as-invasive-ductal-carcinoma/2026-10-22T15:26:37-04:00https://www.scisync.org/2026/10/22/p073-8-efficacy-of-fulvestrant-as-endocrine-therapy-in-hormone-receptor-positive-advanced-breast-cancer/2026-10-22T15:26:39-04:00https://www.scisync.org/2026/10/22/p073-6-efficacy-of-immune-checkpoint-inhibitors-in-triple-negative-breast-cancer-a-systematic-review/2026-10-22T15:26:40-04:00https://www.scisync.org/2026/10/22/p073-1-capivasertib-access-via-cgp-after-cdk4-6i-in-hr-her2-metastatic-breast-cancer-a-retrospective-single-center-study/2026-10-22T15:26:40-04:00https://www.scisync.org/2026/10/22/p072-8-unusual-response-to-endocrine-therapy-in-metastatic-breast-cancer/2026-10-22T15:26:42-04:00https://www.scisync.org/2026/10/22/p072-4-multi-omics-profiling-identifies-il20rb-as-a-novel-regulator-of-emt-and-lymph-node-metastasis-in-breast-cancer/2026-10-22T15:26:43-04:00https://www.scisync.org/2026/10/22/p072-3-predictive-factors-to-cdk4-6-inhibitors-used-in-advanced-breast-cancer/2026-10-22T15:26:43-04:00https://www.scisync.org/2026/10/22/p072-1-profile-and-outcomes-of-pik3ca-and-esr1-mutated-hormone-receptor-positive-metastatic-breast-cancer-an-indian-context/2026-10-22T15:26:44-04:00https://www.scisync.org/2026/10/22/p071-7-post-diagnosis-weight-trajectories-in-case-of-breast-carcinoma-and-factors-associated-with-it/2026-10-22T15:26:45-04:00https://www.scisync.org/2026/10/22/p071-2-efficacy-of-aurora-b-kinase-inhibitors-in-breast-cancer-patients-is-dependent-on-mitotic-checkpoint-regulators/2026-10-22T15:26:45-04:00https://www.scisync.org/2026/10/22/development-and-preclinical-evaluation-of-tetraspecific-antibodies-in-combination-with-ex-vivo-expanded-nk-cells-infusion-for-improved-control-of-esophageal-cancer/2026-10-22T17:24:10-04:00https://www.scisync.org/2026/10/22/clonal-circulating-tumor-cell-mobilization-following-chimeric-antigen-receptor-t-cell-therapy-in-metastatic-castration-resistant-prostate-cancer/2026-10-22T17:24:12-04:00https://www.scisync.org/2026/10/22/extracellular-matrix-collagen-remodeling-predicts-resistance-to-immune-checkpoint-blockade-in-mismatch-repair-deficient-endometrial-cancer/2026-10-22T17:24:13-04:00https://www.scisync.org/2026/10/22/beyond-molecular-mimicry-immune-memory-as-the-missing-dimension-of-cancer-immune-surveillance/2026-10-22T17:24:15-04:00https://www.scisync.org/2026/10/22/reprogramming-the-tumor-microenvironment-from-within-intratumoral-immunoadjuvants-in-cancer-immunotherapy/2026-10-22T17:24:15-04:00https://www.scisync.org/2026/10/22/p070-3-neoadjuvant-chemotherapy-with-pembrolizumab-in-stage-ii-iii-tnbc-at-ho-chi-minh-city-oncology-hospital/2026-10-22T17:26:11-04:00https://www.scisync.org/2026/10/22/p069-9-minimal-residual-disease-driven-adaptive-postoperative-strategy-in-limited-stage-small-cell-lung-cancer-a-case-report/2026-10-22T17:26:12-04:00https://www.scisync.org/2026/10/22/p068-5-evaluation-of-hybrid-deep-and-radiomics-features-for-lung-cancer-classification-in-ct-images/2026-10-22T17:26:12-04:00https://www.scisync.org/2026/10/22/p067-9-high-sensitivity-troponin-t-as-a-predictive-factor-for-immune-checkpoint-inhibitor-associated-myocarditis/2026-10-22T17:26:13-04:00https://www.scisync.org/2026/10/22/p067-5-prognostic-factors-in-advanced-or-recurrent-nsclc-treated-with-ici-plus-chemotherapy-retrospective-study/2026-10-22T17:26:14-04:00https://www.scisync.org/2026/10/22/p067-3-real-world-clinical-outcomes-among-patients-with-ansclc-treated-with-1l-pembrolizumab-combination-regimens-in-japan/2026-10-22T17:26:14-04:00https://www.scisync.org/2026/10/22/p067-2-survivorship-after-2-year-immune-checkpoint-inhibitor-therapy-in-advanced-nsclc-insight-from-korean-national-claim-data/2026-10-22T17:26:15-04:00https://www.scisync.org/2026/10/22/p066-11-effective-treatment-of-leptomeningeal-carcinomatosis-with-erlotinib-and-bevacizumab-in-two-cases-of-egfr-mutant-nsclc/2026-10-22T17:26:16-04:00https://www.scisync.org/2026/10/22/p066-4-central-nervous-system-adverse-events-and-tolerability-of-lorlatinib-in-alk-fusion-positive-nsclc-in-clinical-practice/2026-10-22T17:26:17-04:00https://www.scisync.org/2026/10/22/p066-1-cns-adverse-events-in-patients-with-alk-advanced-nsclc-treated-with-first-line-lorlatinib-in-clinical-settings-in-japan/2026-10-22T17:26:17-04:00https://www.scisync.org/2026/10/21/comparative-analysis-of-photocatalytic-enzymatic-and-chemical-approaches-to-identify-canonical-and-noncanonical-surfaceomes/2026-10-22T17:28:49-04:00https://www.scisync.org/2026/10/22/unstable-immune-cells-linked-to-severe-cancer-immunotherapy-side-effects/2026-10-22T19:21:01-04:00https://www.scisync.org/2026/10/22/p065-3-phase-ii-study-of-necitumumab-chemotherapy-in-lung-squamous-cell-carcinoma-exploratory-analysis-of-wjog14120l-nessie/2026-10-22T19:24:43-04:00https://www.scisync.org/2026/10/22/p065-2-real-world-treatment-patterns-and-duration-in-japanese-patients-with-nsclc-a-retrospective-claims-database-study/2026-10-22T19:24:44-04:00https://www.scisync.org/2026/10/22/p064-5-efficacy-of-neoadjuvant-immunotherapy-in-resectable-nsclc-a-systematic-review/2026-10-22T19:24:45-04:00https://www.scisync.org/2026/10/22/p063-5-conversion-surgery-following-duodenal-stent-placement-in-unresectable-advanced-gastric-cancer-a-case-report/2026-10-22T19:24:46-04:00https://www.scisync.org/2026/10/22/p062-7-a-case-of-severe-febrile-neutropenia-and-cmv-infection-during-treatment-for-irae-pneumonitis-and-hepatitis/2026-10-22T19:24:46-04:00https://www.scisync.org/2026/10/22/p060-6-checkpoint-inhibitor-associated-guillain-barre-like-syndrome-in-hepatocellular-carcinoma-case-report/2026-10-22T19:24:47-04:00https://www.scisync.org/2026/10/22/p060-3-a-case-of-protein-losing-enteropathy-during-zolbetuximab-therapy-in-cldn18-2-positive-gastroesophageal-junction-cancer/2026-10-22T19:24:48-04:00https://www.scisync.org/2026/10/22/p058-3-efficacy-of-immune-checkpoint-inhibitors-in-dmmr-vs-pmmr-metastatic-colorectal-cancer-a-meta-analysis-of-rcts/2026-10-22T19:24:49-04:00https://www.scisync.org/2026/10/22/p057-4-safety-and-efficacy-of-pertuzumab-and-trastuzumab-in-her2-positive-metastatic-colorectal-cancer-comparison-of-iv-and-sc/2026-10-22T19:24:50-04:00https://www.scisync.org/2026/10/22/p057-1-investigation-of-galectin-3-and-p53-in-colorectal-bearing-mouse-model-treated-with-lysiphyllum-strychnifolium-extract/2026-10-22T19:24:51-04:00https://www.scisync.org/2026/10/22/scientists-studied-one-million-immune-cells-and-found-clues-to-future-disease-risk/2026-10-22T21:22:45-04:00https://www.scisync.org/2026/10/22/p056-8-initial-experience-with-the-watch-wait-strategy-for-localised-rectal-cancer-in-a-regional-hospital-in-mallorca-spain/2026-10-22T21:26:00-04:00https://www.scisync.org/2026/10/22/p056-5-circulating-tumor-dna-as-a-biomarker-for-minimal-residual-disease-in-colorectal-cancer-a-systematic-review/2026-10-22T21:26:01-04:00https://www.scisync.org/2026/10/22/p055-1-trastuzumab-deruxtecan-leads-the-adc-era-in-metastatic-colorectal-cancer-evidence-from-a-comprehensive-meta-analysis/2026-10-22T21:26:02-04:00https://www.scisync.org/2026/10/22/p054-8-5-fluorouracil-induced-hyperammonemia-in-a-case-of-recurrent-colon-cancer/2026-10-22T21:26:03-04:00https://www.scisync.org/2026/10/22/p054-5-travel-distance-relative-dose-intensity-and-survival-in-first-line-chemotherapy-for-stage-iv-colorectal-cancer/2026-10-22T21:26:04-04:00https://www.scisync.org/2026/10/22/p054-4-the-role-of-gut-microbiota-in-the-pathogenesis-and-treatment-response-of-gastrointestinal-cancers-a-systematic-review/2026-10-22T21:26:05-04:00https://www.scisync.org/2026/10/22/p053-4-landscape-of-pharmacogenomic-interactions-and-drug-screening-using-patient-derived-organoids-in-colorectal-cancer/2026-10-22T21:26:06-04:00https://www.scisync.org/2026/10/22/p051-8-molecular-and-clinical-profile-of-metastatic-gastric-cancer-in-a-single-spanish-center-a-real-world-cohort/2026-10-22T21:26:07-04:00https://www.scisync.org/2026/10/22/p051-3-association-of-iraes-with-survival-in-patients-with-unresectable-gastric-cancer-treated-with-ici-combined-chemotherapy/2026-10-22T21:26:07-04:00https://www.scisync.org/2026/10/22/p050-7-two-cases-of-conversion-surgery-following-zolbetuximab-based-chemotherapy-for-advanced-gastric-cancer/2026-10-22T21:26:08-04:00https://www.scisync.org/2026/10/22/a-global-livestock-virome-catalog-links-viruses-with-resistome-assembly/2026-10-22T23:24:58-04:00https://www.scisync.org/2026/10/22/p050-5-real-world-experience-of-zolbetuximab-for-cldn18-2-positive-advanced-gastric-cancer-in-saga/2026-10-22T23:25:43-04:00https://www.scisync.org/2026/10/22/p047-7-implementation-of-an-antiemetic-and-infusion-management-protocol-for-zolbetuximab-in-a-medical-oncology-day-hospital/2026-10-22T23:25:44-04:00https://www.scisync.org/2026/10/22/p047-3-comparison-of-nivolumab-combined-chemo-versus-ep-ec-therapy-in-advanced-gastric-and-gastroesophageal-junction-nec/2026-10-22T23:25:45-04:00https://www.scisync.org/2026/10/22/p047-1-pembrolizumab-plus-trastuzumab-as-frontline-therapy-in-her2-positive-gastric-cancer-a-systematic-review/2026-10-22T23:25:47-04:00https://www.scisync.org/2026/10/22/p046-1-predictive-modeling-and-potential-biomarker-exploration-for-neoadjuvant-chemo-immunotherapy-response-in-escc/2026-10-22T23:25:48-04:00https://www.scisync.org/2026/10/22/p045-3-from-hyperprogression-to-hope-salvage-nab-paclitaxel-in-recurrent-oropharyngeal-cancer-on-pembrolizumab/2026-10-22T23:25:49-04:00https://www.scisync.org/2026/10/22/p045-1-isolated-kikuchi-fujimoto-disease-of-the-parotid-gland-a-rare-case-of-extranodal-involvement/2026-10-22T23:25:49-04:00https://www.scisync.org/2026/10/22/p044-2-facilitating-research-on-complimentary-therapies-in-oncology-through-systematic-digital-records-for-evidence-based-care/2026-10-22T23:25:50-04:00https://www.scisync.org/2026/10/22/p041-5-prostact-global-a-phase-3-study-of-177lu-rosopatamab-tetraxetan-plus-soc-vs-soc-alone-in-japanese-patients-with-mcrpc/2026-10-22T23:25:51-04:00https://www.scisync.org/2026/10/22/p041-4-ono-4538-131-phase-ii-study-of-ono-4538-nivolumab-in-patients-with-richters-transformation/2026-10-22T23:25:52-04:00https://www.scisync.org/2026/10/22/scientists-discover-a-hidden-immune-weapon-against-deadly-lung-cancer/2026-10-23T01:23:04-04:00https://www.scisync.org/2026/10/23/o07-3-capacity-building-in-oncology-nursing-impact-of-a-stoma-care-workshop-a-sri-lankan-experience/2026-10-23T01:25:35-04:00https://www.scisync.org/2026/10/23/sy14-1-targeted-therapy-development-in-egfr-and-her2-mutant-nsclc-past-achievements-and-future-directions/2026-10-23T01:25:36-04:00https://www.scisync.org/2026/10/23/mo02-2-treatment-outcomes-according-to-time-of-recurrence-in-esophageal-cancer-patients-undergoing-perioperative-chemotherapy/2026-10-23T01:25:37-04:00https://www.scisync.org/2026/10/23/ps2-1-durvalumab-plus-flot-in-resectable-gastric-gastroesophageal-junction-cancer-in-japan-subgroup-analysis-of-matterhorn/2026-10-23T01:25:38-04:00https://www.scisync.org/2026/10/23/o14-3-nivolumab-chemo-vs-chemo-for-advanced-gc-gejc-eac-post-hoc-os-qol-landmark-analysis-by-bor-from-checkmate-649/2026-10-23T01:25:38-04:00https://www.scisync.org/2026/10/23/o01-2-clinical-utility-of-personalized-ctdna-dynamics-for-predictive-biomarker-in-unresectable-pancreatic-cancer/2026-10-23T01:25:39-04:00https://www.scisync.org/2026/10/23/sy28-1-treatment-advance-and-further-perspectives-in-ld-sclc/2026-10-23T01:25:40-04:00https://www.scisync.org/2026/10/23/sy2-4-unmet-medical-needs-in-cancer-of-unknown-primary-remaining-challenges-and-future-perspectives/2026-10-23T01:25:41-04:00https://www.scisync.org/2026/10/23/o16-3-safety-and-factors-associated-with-effectiveness-of-anamorelin-in-crc-the-final-analysis-of-post-marketing-surveillance/2026-10-23T01:25:41-04:00https://www.scisync.org/2026/10/23/o11-3-blood-re-sampling-improves-detection-of-actionable-gene-alterations-by-liquid-biopsy-real-world-data-in-japan/2026-10-23T01:25:42-04:00https://www.scisync.org/2026/10/22/a-receptor-switch-between-discoidin-domain-receptors-underlies-orthobunyavirus-entry-and-host-range/2026-10-23T03:25:53-04:00https://www.scisync.org/2026/10/23/o05-4-differential-signaling-and-immune-microenvironment-in-parpi-resistance-across-genomic-subtypes/2026-10-23T03:26:16-04:00https://www.scisync.org/2026/10/23/ps3-4-ifinatamab-deruxtecan-i-dxd-in-extensive-stage-small-cell-lung-cancer-japanese-subgroup-analysis-from-ideate-lung01/2026-10-23T03:26:17-04:00https://www.scisync.org/2026/10/23/sy29-3-dose-optimization-strategies-in-oncology-drug-development-a-clinical-pharmacology-perspective/2026-10-23T03:26:18-04:00https://www.scisync.org/2026/10/23/sy18-1-challenges-in-spatial-omics-analysis-and-the-role-of-ai-foundation-models-in-clinical-oncology/2026-10-23T03:26:18-04:00https://www.scisync.org/2026/10/23/sy7-4-the-integration-of-genomic-profiling-with-ai-is-transforming-therapeutic-decision-making-in-oncology-hematology/2026-10-23T03:26:19-04:00https://www.scisync.org/2026/10/23/sy1-4-development-of-biliary-tract-cancer-in-asia/2026-10-23T03:26:20-04:00https://www.scisync.org/2026/10/23/p025-5-base-of-skull-chondrosarcoma/2026-10-23T03:26:21-04:00https://www.scisync.org/2026/10/23/p040-5-telisotuzumab-adizutecan-temab-a-plus-osimertinib-osi-as-1l-treatment-for-unresectable-metastatic-nsclc/2026-10-23T03:26:21-04:00https://www.scisync.org/2026/10/23/p040-3-fusion-a-randomized-phase-ii-study-of-fruquintinib-in-advanced-salivary-gland-cancer-utilizing-a-decentralized-approach/2026-10-23T03:26:22-04:00https://www.scisync.org/2026/10/23/p038-4-clinical-impact-of-dengue-fever-on-cancer-treatment-a-seven-patient-experience/2026-10-23T03:26:23-04:00https://www.scisync.org/2026/10/22/risk-factors-and-outcome-of-children-and-young-adults-with-initially-unresected-nonrhabdomyosarcoma-soft-tissue-sarcoma-an-analysis-from-the-international-soft-tissue-sarcoma-consortium/2026-10-23T05:23:14-04:00https://www.scisync.org/2026/10/22/issue-information-102/2026-10-23T05:23:16-04:00https://www.scisync.org/2026/10/23/p037-1-association-between-pre-transplant-oral-management-and-post-transplant-complications-in-stem-cell-transplantation/2026-10-23T05:26:31-04:00https://www.scisync.org/2026/10/23/p036-8-development-of-a-prediction-model-for-capecitabine-induced-hand-foot-syndrome/2026-10-23T05:26:32-04:00https://www.scisync.org/2026/10/23/p036-4-role-of-ketamine-as-an-adjuvant-for-refractory-cancer-pain-a-systematic-review-of-analgesic-efficacy-and-safety/2026-10-23T05:26:33-04:00https://www.scisync.org/2026/10/23/p035-9-ayurveda-rasayana-therapy-art-helps-reduce-platinum-based-chemotherapy-induced-fatigue-a-retrospective-chart-review/2026-10-23T05:26:33-04:00https://www.scisync.org/2026/10/23/p035-6-efficacy-on-the-use-of-co-injected-dexamethasone-for-oxaliplatin-induced-vascular-pain-in-capeox-%c2%b1-bevacizumab-therapy/2026-10-23T05:26:34-04:00https://www.scisync.org/2026/10/23/p035-4-evaluating-hochuekkito-as-supportive-therapy-in-unresectable-gastrointestinal-cancer-toward-the-amateras-study/2026-10-23T05:26:35-04:00https://www.scisync.org/2026/10/23/p035-2-challenges-in-nutritional-support-for-cancer-patients-implications-for-system-development/2026-10-23T05:26:35-04:00https://www.scisync.org/2026/10/23/p034-3-registry-study-for-symptom-management-and-monitoring-by-phr-app-in-routine-cancer-care-practice/2026-10-23T05:26:36-04:00https://www.scisync.org/2026/10/23/p034-2-perceived-challenges-of-ward-nurses-involved-in-lung-cancer-care-in-the-implementation-of-acp/2026-10-23T05:26:37-04:00https://www.scisync.org/2026/10/23/p033-9-a-rare-case-of-papillary-thyroid-carcinoma-presenting-as-pelvic-bone-metastases-in-a-70-year-old-female/2026-10-23T05:26:37-04:00https://www.scisync.org/2026/10/23/p033-7-impact-of-nasopharyngeal-carcinoma-npc-3d-spheroid-size-on-pdt-therapeutic-efficacy-a-pilot-study/2026-10-23T07:26:25-04:00https://www.scisync.org/2026/10/23/p032-11-local-recurrence-of-adenoid-cystic-carcinoma-of-the-nasal-septum-a-case-report/2026-10-23T07:26:26-04:00https://www.scisync.org/2026/10/23/p032-7-gemcitabine-cisplatin-versus-cisplatin-fluorouracil-as-induction-chemotherapy-in-stage-iii-iva-nasopharyngeal-carcinoma/2026-10-23T07:26:27-04:00https://www.scisync.org/2026/10/23/p032-1-clinical-impact-of-long-term-dysphagia-after-definitive-chemoradiotherapy-in-la-hnscc-patients/2026-10-23T07:26:28-04:00https://www.scisync.org/2026/10/23/p031-9-efficacy-and-safety-of-gemcitabine-plus-cisplatin-for-nasopharyngeal-carcinoma-a-retrospective-analysis-of-five-cases/2026-10-23T07:26:29-04:00https://www.scisync.org/2026/10/23/p031-6-clinical-practice-of-companion-diagnostics-cdx-for-thyroid-cancer-a-single-institution-experience/2026-10-23T07:26:30-04:00https://www.scisync.org/2026/10/23/p030-9-rare-case-of-ewing-sarcoma-with-common-symptom-presentation/2026-10-23T07:26:30-04:00https://www.scisync.org/2026/10/23/p030-8-primary-squamous-cell-carcinoma-of-the-frontal-sinus-a-case-report/2026-10-23T07:26:31-04:00https://www.scisync.org/2026/10/23/p030-1-intracranial-germinoma-in-a-young-adult-male-clinical-presentation-and-management/2026-10-23T07:26:32-04:00https://www.scisync.org/2026/10/23/p029-8-lateral-neck-swelling-diagnostic-probabilities/2026-10-23T07:26:33-04:00https://www.scisync.org/2026/10/22/cytokine-circuits-in-cns-homeostasis-and-disease/2026-10-23T07:27:53-04:00https://www.scisync.org/2026/10/22/gutpath-links-immune-archetypes-and-single-cell-landscapes-in-the-infected-gut/2026-10-23T07:27:55-04:00https://www.scisync.org/2026/10/23/local-t-cell-engager-secretion-reprograms-endogenous-antitumor-immunity-and-enhances-car-t-cell-persistence-in-solid-tumors/2026-10-23T09:24:43-04:00https://www.scisync.org/2026/10/23/sirpa-drives-t-cell-apoptosis-to-promote-immune-evasion-in-hepatocellular-carcinoma/2026-10-23T09:24:45-04:00https://www.scisync.org/2026/10/23/siglec-15-and-its-glycan-ligands-in-tumor-associated-macrophage-biology-and-immunotherapy/2026-10-23T09:24:46-04:00https://www.scisync.org/2026/10/23/sintilimab-plus-eribulin-and-carboplatin-in-patients-with-metastatic-triple-negative-breast-cancer-secure-a-phase-ii-multicenter-trial/2026-10-23T09:24:47-04:00https://www.scisync.org/2026/10/23/p028-9-synchronous-malignancy-gastric-cancer-and-cholangiocarcinoma/2026-10-23T09:26:24-04:00https://www.scisync.org/2026/10/23/p026-4-squamous-cell-carcinoma-of-the-middle-ear-a-case-report/2026-10-23T09:26:25-04:00https://www.scisync.org/2026/10/23/p029-1-advanced-gallbladder-neuroendocrine-carcinoma-with-multiple-metastases-a-case-report/2026-10-23T09:26:26-04:00https://www.scisync.org/2026/10/23/p029-7-b-cell-lymphoma-of-female-reproductive-tract-a-mind-boggling-mystery-of-a-boggy-uterus/2026-10-23T09:26:27-04:00https://www.scisync.org/2026/10/23/p026-5-clinical-characteristics-and-outcomes-of-peritoneal-mesothelioma-a-single-center-experience-in-japan/2026-10-23T09:26:27-04:00https://www.scisync.org/2026/10/23/p025-6-a-systematic-review-and-meta-analysis-ca-153-as-predictive-value-for-ocular-metastasis-from-breast-cancer/2026-10-23T09:26:28-04:00https://www.scisync.org/2026/10/23/p027-6-ulcerating-umbilical-plaque-as-a-rare-presentation-of-extraovarian-primary-peritoneal-carcinoma-a-case-report/2026-10-23T09:26:29-04:00https://www.scisync.org/2026/10/22/capivasertib-plus-abiraterone-in-pten-deficient-de-novo-metastatic-hormone-sensitive-prostate-cancer-updated-survival-analysis-from-capitello-281/2026-10-23T09:26:30-04:00https://www.scisync.org/2026/10/22/neoadjuvant-nivolumab-plus-gemcitabine-cisplatin-followed-by-postsurgical-adjuvant-nivolumab-versus-neoadjuvant-gemcitabine-cisplatin-in-patients-with-muscle-invasive-bladder-cancer-f/2026-10-23T09:26:31-04:00https://www.scisync.org/2026/10/22/overall-survival-with-adjuvant-ribociclib-plus-nonsteroidal-aromatase-inhibitor-in-patients-with-high-risk-hr-her2-early-breast-cancer-six-year-follow-up-of-the-natalee-trial/2026-10-23T09:26:31-04:00https://www.scisync.org/2026/10/23/p028-9-synchronous-malignancy-gastric-cancer-and-cholangiocarcinoma-2/2026-10-23T09:27:58-04:00https://www.scisync.org/2026/10/23/p026-4-squamous-cell-carcinoma-of-the-middle-ear-a-case-report-2/2026-10-23T09:27:59-04:00https://www.scisync.org/2026/10/23/p029-1-advanced-gallbladder-neuroendocrine-carcinoma-with-multiple-metastases-a-case-report-2/2026-10-23T09:27:59-04:00https://www.scisync.org/2026/10/22/active-surveillance-versus-standard-surgery-after-neoadjuvant-chemoradiotherapy-for-oesophageal-cancer-long-term-results-of-a-cluster-randomised-controlled-trial-sano/2026-10-23T09:28:00-04:00https://www.scisync.org/2026/10/22/perioperative-pembrolizumab-or-placebo-plus-neoadjuvant-cisplatin-and-gemcitabine-in-participants-with-muscle-invasive-bladder-cancer-who-are-eligible-for-cisplatin-the-double-blind-phase-iii-keynot/2026-10-23T09:28:01-04:00https://www.scisync.org/2026/10/21/nivolumab-plus-relatlimab-with-platinum-doublet-chemotherapy-versus-nivolumab-with-platinum-doublet-chemotherapy-in-stage-iv-or-recurrent-non-small-cell-lung-cancer-clinical-translational-and-patie/2026-10-23T09:28:02-04:00https://www.scisync.org/2026/10/20/the-esmo-scale-for-clinical-actionability-of-molecular-targets-version-2-escat-v2-an-evidence-based-framework-for-ranking-alterations-as-actionability-and-resistance-biomarkers-in-precision-oncolo/2026-10-23T09:28:02-04:00https://www.scisync.org/2026/10/19/corrigendum-to-ovarian-reserve-as-a-measure-of-adjuvant-chemotherapy-benefit-in-hormone-receptor-positive-hr-positive-her2-negative-node-positive-breast-cancer-in-swog-s1007-rxponder/2026-10-23T09:28:03-04:00https://www.scisync.org/2026/10/22/epidemiologic-stability-despite-rhinovirus-diversity-a-clearer-path-toward-targeted-prevention/2026-10-23T09:28:52-04:00https://www.scisync.org/2026/10/23/a-tiny-defect-in-a-crystal-reveals-a-big-quantum-surprise/2026-10-23T09:31:45-04:00https://www.scisync.org/2026/10/22/first-human-infected-with-rare-livestock-pathogen-what-we-know-about-shamonda-virus/2026-10-23T11:28:20-04:00https://www.scisync.org/2026/10/22/nf-%ce%bab-phosphorylation-controls-enhancer-selection-to-shape-the-inflammatory-gene-program/2026-10-23T11:29:21-04:00https://www.scisync.org/2026/10/21/how-federal-policy-changes-are-affecting-cancer-disparities-research-findings-from-an-aacr-survey/2026-10-23T13:24:35-04:00https://www.scisync.org/2026/10/22/m7g-modification-in-mrna-cooperates-with-qki-to-promote-homologous-recombination-repair/2026-10-23T13:28:44-04:00https://www.scisync.org/2026/10/23/articles-perioperative-chemotherapy-and-stereotactic-body-radiotherapy-versus-perioperative-chemotherapy-alone-in-patients-with-high-risk-localised-pancreatic-cancer-masterplan-an-open-label-ph/2026-10-23T15:21:53-04:00https://www.scisync.org/2026/10/22/anatid-herpesvirus-1-us10-recruits-trim13-to-ubiquitinate-sting-for-autophagic-degradation-and-immune-suppression/2026-10-23T15:24:04-04:00https://www.scisync.org/2026/10/23/an-autonomous-macrophage-nociceptor-mechanosensory-relay-drives-chronic-visceral-pain/2026-10-23T17:26:53-04:00https://www.scisync.org/2026/10/23/ilc2-derived-il-9-promotes-eosinophil-mediated-antitumor-activity/2026-10-23T17:26:54-04:00https://www.scisync.org/2026/10/23/news-proposed-mexican-reform-would-set-60-day-limit-for-cancer-treatment/2026-10-23T19:23:36-04:00https://www.scisync.org/2026/10/23/news-us-epa-research-and-oversight-on-carcinogens-are-in-disarray-critics-contend/2026-10-23T19:23:37-04:00https://www.scisync.org/2026/10/23/newly-discovered-protein-controls-the-space-between-mitochondrial-membranes/2026-10-23T23:28:05-04:00https://www.scisync.org/2026/10/23/researchers-call-for-microbiome-moonshot-to-tackle-chronic-diseases/2026-10-23T23:28:07-04:00https://www.scisync.org/2026/10/24/twiv-1368-clinical-update-with-dr-daniel-griffin/2026-10-24T01:24:59-04:00https://www.scisync.org/2026/10/23/enterovirus-a71-exploits-peripheral-circulating-extracellular-vesicles-to-facilitate-blood-brain-barrier-permeability/2026-10-24T01:25:46-04:00https://www.scisync.org/2026/10/23/body-mass-index-at-diagnosis-postdiagnosis-change-and-role-of-metabolic-comorbidities-in-relation-to-survival-in-nonmetastatic-renal-cell-carcinoma-patients/2026-10-24T03:22:20-04:00https://www.scisync.org/2026/10/23/generative-artificial-intelligence-in-medical-oncology-a-clinically-focused-narrative-review-of-large-language-vision%e2%80%90language-and-agentic-artificial-intelligence-systems/2026-10-24T03:22:21-04:00https://www.scisync.org/2026/10/22/atirmociclib-and-fulvestrant-for-patients-with-hr-her2-advanced-metastatic-breast-cancer-who-progressed-on-a-prior-cyclin-dependent-kinase-4-6-inhibitor-primary-analysis-of-the-randomized-f/2026-10-24T03:25:36-04:00https://www.scisync.org/2026/10/22/pembrolizumab-plus-chemotherapy-for-hr-her2%e2%88%92-pd-l1%e2%80%92positive-advanced-breast-cancer-final-analysis-of-the-phase-3-keynote-b49-study/2026-10-24T03:25:37-04:00https://www.scisync.org/2026/10/23/adjuvant-chemotherapy-with-cisplatin-and-gemcitabine-compared-to-standard-of-care-after-curative-intent-resection-of-cholangiocarcinoma-and-muscle-invasive-gallbladder-carcinoma-acticca-1-aio-hep-011/2026-10-24T05:26:26-04:00https://www.scisync.org/2026/10/23/overall-survival-from-the-phase-iii-postmonarch-trial-of-abemaciclib-plus-fulvestrant-versus-placebo-plus-fulvestrant-for-hr-her2-advanced-breast-cancer-following-progression-on-a-prior-cdk4-6-inhi/2026-10-24T05:26:28-04:00https://www.scisync.org/2026/04/27/asap-multiscale-modeling-of-the-bacterial-ribosome-to-identify-potential-peptide-modulators-and-their-allosteric-effects/2026-10-24T05:30:02-04:00